Enadenotucirev is an investigational oncolytic virus that is in clinical trials for various cancers.

[1] It is an oncolytic A11/Ad3 Chimeric Group B Adenovirus, previously described as ColoAd1.

[2] Enadenotucirev has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents.

[citation needed] The T-SIGn vectors at clinical study stage are:[citation needed] In Jan 2015 the European Medicines Agency's (EMA) Committee for Orphan Medical Products (COMP) designated enadenotucirev as an orphan medicinal product for the treatment of ovarian cancer.

[5] As of June 2019[update], there are two active phase 1 trials: OCTAVE (in ovarian cancer)[6] and SPICE (in multiple solid tumor indications) [7] Of the T-SIGn viruses, NG-350A has an ongoing clinical study.